Дізнайтеся про найкращі ціни та клініки з лікування лейкемії (рака крові) у Китаї у 2026 році

China pioneered the world first cure for acute promyelocytic leukemia using differentiation therapy. It also leads in cellular immunotherapy with the largest volume of active CAR-T trials. Leading centers utilize the Beijing Protocol for high-success haploidentical stem cell transplants from family donors.

• Beijing Protocol: Enables successful `half-matched` family donor transplants for patients lacking full matches.
• Pioneering therapy: Employs ATRA and arsenic trioxide to reach 95% survival in APL.
• CAR-T innovations: Offers dual-target therapies (CD19/CD22) and rapid cell manufacturing within 36 hours.
• Inaticabtagene autoleucel: First domestic CAR-T therapy approved for B-cell acute lymphoblastic leukemia.

Bookimed Expert Insight: China is a leader in pediatric hematology cases due to high patient volumes. Dr. Xiao Juan at Beijing Kyoto Children Hospital brings over 20 years of experience to high-risk infant leukemia. This deep expertise often allows Chinese specialists to accept complex cases that other international centers might decline.

Patient Consensus: Patients note that China provides faster access to experimental combinations and bispecific antibodies through clinical trials. Many emphasize the importance of choosing established Beijing or Shanghai centers that offer dedicated English-language support.

Chinese leukemia survival rates vary significantly by type. Specific protocols for childhood Acute Lymphoblastic Leukemia and Chronic Lymphocytic Leukemia now match or exceed Western benchmarks. While national averages often trail Global North standards, urban specialty hematology centers report comparable outcomes using advanced therapies.

• Childhood leukemia: 5-year survival for pediatric ALL reaches 85% to 91% in urban centers.
• Adult leukemia: Adult AML survival remains lower at 24% for national Chinese averages.
• Chronic lymphocytic: Chinese patients show 85% 5-year survival with targeted therapies versus 65% elsewhere.
• Cellular immunotherapy: Access to CAR T-cell therapy boosts survival by 20% to 30% for refractory cases.

Bookimed Expert Insight: Data reveals a survival advantage in China specifically for patients seeking CAR T-cell therapy. While Western centers follow standardized drug approvals, Beijing centers like GoBroad Boren Hospital provide rapid access to these trials. A CAR-T package costs approximately $100,250 and includes 30 days of hospitalization. This extensive inpatient monitoring explains why urban success rates for complex cases rival top-tier American institutions.

Patient Consensus: Patients note that seeking care in Tier-1 city hospitals is vital for matching Western success rates. Those participating in clinical trials report significantly better outcomes for difficult, relapsed cases than with standard chemotherapy.

China integrates Traditional Chinese Medicine (TCM) with modern leukemia therapy by combining Western protocols like chemotherapy and CAR T-cell therapy with herbal adjuncts. This multimodal approach uses TCM to mitigate toxicity, boost immune recovery, and improve survival rates. Major Class A Level III hospitals in Beijing coordinate these integrated treatments.

• Adjuvant support: Herbs like Astragalus reduce chemotherapy side effects like nausea and fatigue.
• Derived medications: Arsenic Trioxide and Homoharringtonine are TCM-derived drugs for specific leukemia subtypes.
• Immune regulation: Fu Zheng therapies help restore hematopoietic function and white blood cell counts.
• Maintenance care: Practitioners use personalized herbal decoctions to help prevent relapse after clinical remission.

Bookimed Expert Insight: Data from top-tier facilities like Yanda International Hospital show that integration is most effective when performed in JCI-accredited environments. While a CAR T-cell therapy package at specialized centers like Beijing GoBroad Boren Hospital costs around $100,000, the addition of hospital-regulated TCM often focuses on the 30-day recovery phase. Choosing a hospital that manages both ensures that herbal supplements do not interfere with high-tech treatments like CAR T-cell infusions.

Patient Consensus: Patients note it is important to use only hospital-prescribed herbs to avoid liver toxicity. Many find that combining Western chemo with TCM decoctions helps their blood counts recover faster during long-term maintenance.

The Beijing Protocol is a pioneering medical method for haploidentical stem-cell transplantation. It allows patients to receive transplants from family members who are only a 50% genetic match. This technique effectively solves donor shortages by ensuring nearly every patient has a potential donor within their family.

• Donor accessibility: Parents or siblings can serve as donors regardless of a perfect genetic match.
• Success rates: Approximately 99% of patients achieve sustained myeloid engraftment using this specialized protocol.
• Graft management: Surgeons use unmanipulated grafts without removing T-cells outside of the body.
• Immune tolerance: Precise doses of Anti-Thymocyte Globulin (ATG) help prevent Graft-Versus-Host Disease (GVHD).

Bookimed Expert Insight: This protocol is highly effective for urgent high-risk cases where finding a matched donor takes too long. Beijing GoBroad Boren Hospital and Kyoto Children's Hospital are key hubs for these transplants. While standard CAR-T therapy packages can cost around $100,000, specialized stem-cell protocols often require 30-day hospitalizations for safe engraftment.

Patient Consensus: Patients note that recovery is often faster than expected, with engraftment typically occurring within 14 days. They emphasize the importance of staying in China for two years of follow-up to ensure long-term monitoring is consistent.

International patients undergoing CAR T-cell therapy in China typically stay for 3 to 8 weeks. This period includes cellular collection, laboratory manufacturing, and post-infusion monitoring. Specialized centers in Beijing and Shanghai often require at least 30 days of direct hospitalization for safety.

• Hospitalization phase: Packages at Beijing GoBroad Boren Hospital include 30 days of inpatient stay.
• Manufacturing timeline: T-cell expansion usually takes 14 to 21 days in Chinese laboratories.
• Monitoring window: Critical observation for cytokine release syndrome lasts 2 to 4 weeks post-infusion.
• Total duration: Most patients should plan for 2 to 3 months in the country.

Bookimed Expert Insight: While standard CAR-T cell manufacturing takes up to 3 weeks, some Chinese facilities use specialized platforms that reduce this to 36 hours. If you select a clinic with this technology, your overall stay may decrease. However, mandatory monitoring for side effects like neurotoxicity remains strict regardless of how fast cells are produced.

Patient Consensus: Patients emphasize that outpatient CAR-T is rare in China. Most recommend staying within 2 hours of the hospital for several weeks after discharge to manage potential fevers.